Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu for Post-Surgical Recovery: Evidence, Dosing, and Clinical Use

By
Published Updated Last reviewed
11 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Regulatory status / No FDA-approved GHK-Cu drug [1]
  • Injectable form / Not FDA-approved; FDA cites an immunogenicity risk [3][4]
  • Venous ulcer trial, 86 patients / 0.4% copper tripeptide cream no better than inert vehicle placebo [5]
  • Laser-resurfacing trial, 13 patients / No objective difference; questionnaire favored GHK-Cu (P=.04) [2]
  • Established post-surgical dose / No FDA-approved GHK-Cu dose exists; the only drug-style human trial used a 0.4% cream for venous stasis ulcers, which does not establish a surgical dose [1][5]

What Human Evidence Exists?

GHK-Cu is the copper complex of a tripeptide found in human plasma, saliva and urine [6].

The closest human trials were topical and in other conditions. In a prospective randomized evaluator-blinded trial of 86 evaluable patients with venous stasis ulcers, a 0.4% tripeptide copper complex cream performed no differently from an inert vehicle placebo on ulcer size, while silver sulfadiazine 1% did reduce ulcer size [5].

The other trial resurfaced circumoral skin with a CO2 laser, then compared skin care with and without GHK-Cu; 13 patients completed. Computer analysis and blinded evaluators found no significant difference in resolution of redness, wrinkles or overall skin quality, while a patient questionnaire showed a significant difference favoring GHK-Cu (P=.04) [2].

A 2026 systematic review that kept 64 records described the human literature as thin and fragmented: most randomized trials are small, run on facial cosmetic creams, and microneedle delivery had not been tested in a registered, adequately powered human randomized trial [7]. A 2008 review by the researcher who proposed GHK states that GHK-Cu stimulates wound healing in humans and improves hair transplant success, but its abstract gives no trial details [11].

Is There a Post-Surgical Dose?

No FDA-approved GHK-Cu product or dose exists [1]. Cosmetic strengths are set by manufacturers and cosmetics are not FDA-approved before sale. The only drug-style human trial found used a 0.4% tripeptide copper complex cream for venous stasis ulcers [3][5].

Regulatory Status and Safety

GHK-Cu is not copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children; that is a different compound [8]. Copper peptide creams and serums are sold as cosmetics because cosmetics need no FDA approval before sale; claims to treat disease or change the body's structure or function make a product a drug [3]. Injectable GHK-Cu is not a cosmetic and is not FDA-approved [3].

Non-injectable GHK-Cu sits in category 1 of FDA's interim compounding policy, the group under evaluation for the bulks list [1][9]. Injectable GHK-Cu is in the 'nominated but withdrawn' table on FDA's page on bulk substances that may present significant safety risks, which states that compounded injectable GHK-Cu may pose an immunogenicity risk from aggregation and peptide-related impurities and that human safety data are limited [4].

Frequently asked questions

Is GHK-Cu FDA-approved for post-surgical recovery?
No. No FDA-approved drug is known to contain GHK-Cu, so no approved product, indication or dose exists for surgical recovery [1].
What dose is used after surgery?
None is established. Cosmetic strengths are set by manufacturers without FDA review, and the only drug-style human trial found used a 0.4% tripeptide copper complex cream [5].
Is injectable GHK-Cu safe?
FDA states that compounded injectable GHK-Cu may pose an immunogenicity risk from aggregation and peptide-related impurities and that human safety data are limited [4]. Injectable GHK-Cu is not FDA-approved [3].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  3. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  5. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  6. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
  7. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
  8. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  9. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA
  10. U.S. National Library of Medicine, DailyMed. COPPER (cupric chloride) prescribing information. COPPER (cupric chloride) label
  11. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. The human tri-peptide GHK and tissue remodeling
Evidence overview for GHK-Cu for Post-Surgical Recovery: Evidence, Dosing, and Clinical Use